NHS green light for new ovarian cancer drug

Professor Jonathan Ledermann (UCL Cancer Institute) said: "The positive Nice guidance for olaparib represents a turning point for how women with ovarian cancer and a BRCA mutation are treated by the NHS in England". Read: Guardian